Jazz Pharmaceuticals plc diskutieren
Jazz Pharmaceuticals plc
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Aktie / Pharmazeutika / Mid Cap /
166,70 €
12,93 %
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target lowered by analysts at JPMorgan Chase & Co. from $204.00 to $199.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Royal Bank Of Canada from $151.00 to $155.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Morgan Stanley from $185.00 to $205.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) was given a new $194.00 price target on by analysts at Royal Bank Of Canada. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Robert W. Baird from $160.00 to $209.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Wells Fargo & Company from $170.00 to $235.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "buy" rating reaffirmed by analysts at TD Cowen.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) had its price target raised by Bank of America Corporation from $263.00 to $275.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) had its price target raised by Wells Fargo & Company from $235.00 to $250.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) had its price target raised by Royal Bank Of Canada from $191.00 to $195.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals (JAZZ) had its price target raised by Morgan Stanley from $225.00 to $226.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Neueste Beiträge
Barrington_Research in Merit Medical Systems diskutieren